Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-Type natriuretic peptide in Patients with chronic heart failure

Circulation: Heart Failure

Volumn 4, Issue 3, 2011, Pages 355-360

  Miller, Wayne L ^a   Phelps, Mary A ^a   Wood, Christina M ^a   Schellenberger, Ute ^b   Van Le, Anh ^c   Perichon, Regis ^c   Jaffe, Allan S ^a  

^a MAYO CLINIC   (United States)

^b Pioneer Hi Bred International   (United States)

^c Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

BNP 1 32; BNP fragments; Cardiomyopathy; Corin; Heart failure; Mass spectrometry immunoassay; Natriuretic peptides; ProBNP

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; BIOLOGICAL MARKER; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD; CARDIAC PATIENT; CLINICAL LABORATORY; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HEART FAILURE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DEGRADATION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES;

EID: 79960584348     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.110.960260     Document Type: Article

References (23)

1. Latini R, Masson S, Wong M, Barlera S, Carretta E, Staszewsky L, Vago T, Maggioni AP, Anand IS, Tan LB, Tognoni G, Cohn JN, Val-HeFT Investigators. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med. 2006;119:70. e23-e30.
2. Nishii M, Inomata T, Takehana H, Naruke T, Yanagisawa T, Moriguchi M, Takeda S, Izumi T. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure. J Am Coll Cardiol. 2008;51: 2329-2335. (Pubitemid 351783361)
3. Miller WL, Hartman KA, Burritt MF, Grill DE, Rodeheffer RJ Jr, Jaffe AS. Serial biomarker measurements in ambulatory patients with chronic heart failure: The importance of change over time. Circulation. 2007; 116:249-257. (Pubitemid 47196560)
4. Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, Apple FS, Maisel AS, Pollitt NS, Protter AA. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol. 2007;49:1071-1078. (Pubitemid 46349497)
5. Lam CSP, Burnett JC Jr, Costello-Boerrigter L, Rodeheffer RJ, Redfield MM. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol. 2007;49:1193-1202. (Pubitemid 46400332)
6. Hammerer-Lercher A, Halfinger B, Sarg B, Mair J, Puschendorf B, Griesmacher A, Guzman NA, Lindner HH. Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem. 2008;54:858-865. (Pubitemid 351671596)
7. Waldo SW, Beede J, Isakson S, Villard-Saussine S, Farej J, Clopton P, Fitzgerald RL, Maisel AS. Pro-B-type natriuretic peptide levels in acute decompensated heart failure. J Am Coll Cardiol. 2008;51:1874-1882. (Pubitemid 351615249)
8. Seferian KR, Tamm NN, Semenov AG, Mukharyamova KS, Tolstaya AA, Koshkina EV, Kara AN, Krasnoselsky MI, Apple FS, Esakova TV, Filatov VL, Katrukha AG. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem. 2007;53:866-873. (Pubitemid 46744242)
9. Hawkridge AM. Heublein DM. Bergen HR. Cataliotti A. Burnett JC. Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A. 2005;102:17442-17447. (Pubitemid 41740885)
10. Giuliani I, Rieunier F, Larue C, Delagneau J-F, Granier C, Pau B, Ferriere M, Saussine M, Cristol JP, Dupuy AM, Merigeon E, Merle D, Villard S. Assay for measurement of intact B-type natriuretic peptide prohormone in blood. Clin Chem. 2006;2:1054-1061. (Pubitemid 43794417)
11. Niederkofler EE, Kiernan UA, O'Rear J, Menon S, Saghir S, Protter AA, Nelson RW, Schellenberger U. Detection of endogeous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail. 2008;1:258-264.
12. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM, Burnett JC Jr. Immunoreactivity and guanosine 3-, 5-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension. 2007;49:1114-1119.
13. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpe S, DeMeester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clinical Chemistry. 2006;52:82-87. (Pubitemid 43032470)
14. Luckenbill KN, Christenson RH, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, Tate J, Wu AHB, Ler R, Apple FS. Cross-reactivity of BNP, NT-proBNP, and proBNP in commerical assays: Preliminary observations from the IFCC Committee for standardization of markers of cardiac damage Clin Chem. 2008;54:619-620.
15. Schellenberger U, O'Rear J, Guzzetta A, Jue RA, Protter AA, Pollitt NS. The precursor to -type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys. 2006;451:160-166.
16. Belenky A, Smith A, Zhang B, Lin S, Despres N, Wu AHB, Bluestein BI. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta. 2004;340: 163-172. (Pubitemid 38167520)
17. Mongia SK, Al'ula SL, Apple FS, Ler R, Murakaimi MM, Roberts WL. Performance characteristics of the Architect® brain natriuretic peptide (BNP) assay: a two site study. Clin Chim Acta. 2008;391:102-105.
18. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem. 2004;50:234-236. (Pubitemid 38125732)
19. Quantikine® Human Corin Immunoassay, Catalog Number DCRNOO. Minneapolis, MN: R&D Systems, Inc; 2007.
20. Semenov AG, Tamm NN, Seferian KR, Postnikov AB, Karpova NS, Serebryanaya DV, Koshkina EV, Krasnoselsky MI, Katrukha AG. Processing of Pro-B-Type natriuretic peptide: furin and corin as candidate convertases. Clin Chem. 2010;56:1166-1176.
21. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC Jr. Des-Serine-Proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol. 2007;292:R897-R901. (Pubitemid 46207745)
22. Semenov AG, Postnikov AB, Tamm NN, Seferian KR, Karpova NS, Bloshchitsyna MN, Koshkina EV, Krasnoselsky MI, Serebryanaya DV, Katrukha AG. Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin Chem. 2009;55:489-498.
23. Seferian KR, Tamm NN, Semenov AG, Tolstaya AA, Koshkina EV, Krasnoselky MI, Postnikov AB, Serebryanaya DV, Apple FS, Murakami MA, Katrukha AG. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem. 2008;54:866-873. (Pubitemid 351671597)